Note 13 - Royalty and other income

The Company had a license agreement with Qiagen that began in 2005, whereby the Company earned quarterly running royalties on the net sales of Qiagen products subject to a license until the underlying patent expired in April 2018. During the years ended July 31, 2019, 2018 and 2017, the Company recorded royalty income under the agreement of approximately $0, $712 and $1,205 respectively, which is included in the Life Sciences products segment.